Thibaud Valentin

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)

Thibaud Valentin, Axel Le Cesne, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2016 · 187 citations

Neuro-oncology, Surgical Oncology, Tumoral Pathology +7

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial

Axel Le Cesne, Jean‐Yves Blay, Julien Dômont et al. · The Lancet Oncology · 2015 · 94 citations

Surgical Oncology, Soft-tissue Sarcoma, Randomised Phase 2 +2

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

Jean‐Yves Blay, Sylvie Chevret, Axel Le Cesne et al. · The Lancet Oncology · 2023 · 68 citations

Oncology, Pathology, Ultra-rare Sarcomas +4

Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)

Thibaud Valentin, Charles Fournier, Nicolas Penel et al. · Investigational New Drugs · 2013 · 59 citations

Surgical Oncology, Tumoral Pathology, Malignant Disease +8

Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study

Anastasia Constantinidou, Nicolas Sauvé, Silvia Stacchiotti et al. · ESMO Open · 2020 · 54 citations · Full text